SLAM
BIVV

Swiss Life Asset Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Swiss Life Asset Management’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,779
Closed -$615K – 529
2017
Q3 		$615K Hold
10,779
– – 0.02% 359
2017
Q2 		$649K Hold
10,779
– – 0.02% 382
2017
Q1 		$587K Buy
+10,779
New +$531K 0.02% 375

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Swiss Life Asset Management's BIVV Position: Q4 2017 in Review

Swiss Life Asset Management sold out of Bioverativ Inc. Common Stock (BIVV) in Q4 2017, closing a stake of 10,779 shares — an estimated $615K sold.

Swiss Life Asset Management first reported a position in BIVV in Q1 2017 and held it in 3 quarters. The position peaked at $649K in Q2 2017. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • Swiss Life Asset Management reported no remaining Bioverativ Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Swiss Life Asset Management sold 10,779 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $615K.
  • Swiss Life Asset Management first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 3 quarters.
  • Swiss Life Asset Management's Bioverativ Inc. Common Stock position peaked at $649K in Q2 2017.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on Swiss Life Asset Management's 13F filing for Q4 2017, filed 29 Dec 2025.